Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis

Table 3 Meta-analysis of VDR ApaI polymorphism and prostate cancer risk

		Homozygote (AA vs. aa)			Heterozygote (Aa vs. aa)			Dominant model (AA + Aa vs. aa)			Recessive model (AA vs. Aa + aa)
Analysis	N	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)
Overall	9	0.97 (0.76–1.25)	0.85	51.1	1.00 (0.88–1.13)	0.99	28.8	0.98 (0.87–1.10)	0.79	0	0.97 (0.85–1.01)	0.64	0
Ethnicity
Caucasian	4	0.81 (0.66–1.01)	0.06	11.0	1.01 (0.85–1.19)	0.91	20.8	0.94 (0.81–1.10)	0.46	20.8	0.92 (0.78–1.06)	0.25	0
African American	2	1.54 (0.74–3.19)	0.24	57.9	1.16 (0.84–1.60)	0.35	0	1.27 (0.94–1.72)	0.12	0	0.92 (0.65–1.29)	0.63	0
Asian	6	1.05 (0.69–1.58)	0.82	36.2	0.90 (0.71–1.14)	0.40	49.0	0.93 (0.76–1.16)	0.56	0	1.24 (0.92–1.66)	0.14	0
Source of control
PB	8	1.03 (0.77–1.38)	0.82	60.1	1.05 (0.91–1.20)	0.52	42.9	1.02 (0.90–1.16)	0.72	0	0.97 (0.85–1.11)	0.64	17.8
HB	4	0.82 (0.50–1.34)	0.43	29.3	0.83 (0.63–1.10)	0.20	0	0.84 (0.65–1.09)	0.18	0	0.98 (0.69–1.38)	0.92	0
HWE in controls
Yes	10	0.96 (0.76–1.21)	0.733	36.6	1.01 (0.89–1.15)	0.90	0	0.99 (0.87–1.12)	0.86	0	0.93 (0.82–1.06)	0.29	0
No	2	0.86 (0.19–3.86)	0.84	86.7	0.91 (0.59–1.40)	0.66	85.6	0.98 (0.88–1.10)	0.74	0	1.56 (0.99–2.46)	0.05	0

P P values for Z test, OR odds ratio, CI confidence intervals, HB hospital–based studies, PB population-based studies, HWE Hardy–Weinberg equilibrium, NR not reported